Prague Med. Rep. 2016, 117, 68-72
https://doi.org/10.14712/23362936.2016.7
Terlipressin Induced Severe Hyponatremia
References
1. , A., Ruiz del Arbol, L., Planas, R., Albillos, A., Bañares, R., Calès, P., Pateron, D., Bernard, B., Vinel, J. P., Bosch, J. (2000) Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology 32(3), 471–476.
<https://doi.org/10.1053/jhep.2000.16601>
2. , F., Ruiz del Arbol, L., Bañares, R., Planas, R., Bosch, J. (1996) Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology 111(5), 1291–1299.
3. , J. G., Cobden, I., Lishman, A. H., Record, C. O. (1982) Controlled trial of terlipressin (“Glypressin”) versus vasopressin in the early treatment of oesophageal varices. Lancet 2(8289), 66–68.
<https://doi.org/10.1016/S0140-6736(82)91689-0>
4. , G., Sanyal, A. J., Grace, N. D., Carey, W.; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology (2007) Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 46(3), 922–938.
<https://doi.org/10.1002/hep.21907>
5. , Y. J., Bae, E. J., Hwang, K., Jeon, D. H., Jang, H. N., Cho, H. S., Chang, S. H., Park, D. J. (2013) Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis. Springerplus 2, 519.
<https://doi.org/10.1186/2193-1801-2-519>
<PubMed>
6. , A., Bendtsen, F., Pedersen, E. B., Holstein-Rathlou, N. H., Møller, S. (2008) Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects. Am. J. Physiol. Renal Physiol. 295(5), F1295–F1300.
<https://doi.org/10.1152/ajprenal.90407.2008>
7. , A., Pedersen, E. B., Møller, S., Bendtsen, F. (2011) Effects of the vasopressin agonist terlipressin on plasma cAMP and ENaC excretion in the urine in patients with cirrhosis and water retention. Scand. J. Clin. Lab. Invest. 71(2), 112–116.
<https://doi.org/10.3109/00365513.2010.537369>
8. , F. H., Canbay, A., Gerken, G., Broelsch, C. E. (2007) Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Rev. Gastroenterol. Hepatol. 1(2), 207–217.
<https://doi.org/10.1586/17474124.1.2.207>
9. , R. H. (2015) Disorders of plasma sodium – Causes, consequences, and correction. N. Engl. J. Med. 372(1), 55–65.
<https://doi.org/10.1056/NEJMra1404489>
10. , S. Y., Seo, Y. S., Jung, C. H., Kim, T. H., Kim, E. S., Keum, B., Kim, J. H., An, H., Yim, H. J., Yeon, J. E., Jeen, Y. T., Lee, H. S., Chun, H. J., Byun, K. S., Um, S. H., Kim, C. D., Ryu, H. S. (2015) Risk factors for developing hyponatremia during terlipressin treatment: a retrospective analyses in variceal bleeding. J. Clin. Gastroenterol. 49(7), 607–612.
<https://doi.org/10.1097/MCG.0000000000000217>
